CARsgen Therapeutics
CARsgen Therapeutics developed satri-cel, the first CAR-T approved for a solid tumour (gastric cancer, China).
Satricabtagene autoleucel (CLDN18.2), zevor-cel (BCMA, China), allogeneic and GPC3 programmes.
Pages like this
not linked directly; found by shared links- PersonChangsong Qi
Shares Satricabtagene autoleucel, Peking University Cancer Hospital, Gastric & gastro-oesophageal junction cancer.
- CompanyRemeGen
Shares Peking University Cancer Hospital, Gastric & gastro-oesophageal junction cancer.
- IdeaPeritoneal-directed therapy for gastric cancer
Shares Satricabtagene autoleucel, Gastric & gastro-oesophageal junction cancer.
- IdeaIn vivo CAR-T against solid-tumour antigens
Shares Satricabtagene autoleucel, Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma.
- IdeaRapid diagnostic centres for people with vague but worrying symptoms
Shares Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma.
- PairingCLDN18.2 antibody first line → CLDN18.2 ADC or CAR-T on progression
Shares Satricabtagene autoleucel, Gastric & gastro-oesophageal junction cancer.
- TargetClaudin 18.2
Shares Lin Shen, Satricabtagene autoleucel, Peking University Cancer Hospital, Gastric & gastro-oesophageal junction cancer.
- IdeaDedicated cohorts for patients with performance status 2 in first-line trials
Shares Gastric & gastro-oesophageal junction cancer, Pancreatic ductal adenocarcinoma.